Imprimis Pharmaceuticals Inc (IMMY)

[ronk]

The Express Scripts news is really interesting. Back in July 2014 Express Scripts dramatically scaled back coverage of compounded medications.

http://t.union-bulletin.com/news/2014/jul/11/express-scripts-cuts-payments-customized-drugs/?

Interesting that Express Scripts have noticed the value to the patient with this story. Hopefully, with a successful rollout of the daraprim alternative, they may realize there is a niche market and potential profitability in the compounding pharmacy industry as a disruptive technology for an exisitng problem with healthcare costs. With a market cap of 58.7 billion, they're not a bad friend to have.